ClinicalTrials.gg
CompletedNCT05657691Updated Jan 22, 2025

Xanamem® in Adults with Major Depressive Disorder and Impaired Cognition (XanaCIDD)

A Phase 2 interventional study of Xanamem™ and Placebo in Major Depressive Disorder, MDD and Cognitive Impairment, sponsored by Actinogen Medical. Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Actinogen Medical · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 67 studies in Depressive Disorder, Major with a site in Australia — 11 open to participants now, 12 under way, 7 of them phase 3. Depressive Disorder, Major · Australia.

Enrollment
31st of 66
167 · median 159
Started
2022
with 2 others
Phase 2
17 of 67
none open now
Registered
54th of 67
by date

Among the 67 studies in Depressive Disorder, Major with a site in Australia, this one is the 31st largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2022, is one of 17 in phase 2, and was the 54th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

11 of the 67 studies in Depressive Disorder, Major with a site in Australia are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Depressive Disorder, Major with a site in Australia, or all of them as a file.
02

Study summary

Xanamem is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).

This XanaCIDD Phase II study in MDD is to investigate the safety and efficacy of Xanamem™ in treating patients with cognitive and depressive symptoms. Trial participants will be randomized to either receive 10mg of Xanamem™ once daily or a Placebo at a 1:1 ratio in a double-blinded fashion.

03

Conditions studied

  • Major Depressive Disorder
  • MDD
  • Cognitive Impairment

Keywords

  • Xanamem
  • UE2343
  • Actinogen
  • Cortisol
  • 11β-HSD1
  • 11-beta-Hydroxysteroid Dehydrogenase Type 1
  • emestedastat
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female aged 18 to 75, inclusive.
  • Positive MDD primary diagnosis confirmed by the Mini-International Neuropsychiatric Interview (MINI).
  • Persistent depressive symptoms as determined by a Hamilton Depression Rating Scale (HAM-D) ≥ 17 at Screening.
  • Cognitive abilities on a coding test > 0.5 standard deviations below expected.
  • Self-reported subjective cognitive dysfunction.
  • Currently or previously treated with a stable dose of a first- or antidepressant that is approved for the treatment of depression (but not a tricyclic antidepressant, monoamine oxidase inhibitor, or vortioxetine). If on current treatment, dose must be stable for at least 6 weeks.
  • Smokers are eligible if they are able to comfortably abstain from nicotine for 2 hours prior to scheduled cognitive assessments.
  • Able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.
  • Must provide written to participate in the trial and be willing and able to comply with the requirements of the protocol and complete all trial visits.

Key Exclusion Criteria:

  • Active suicidal ideation within the previous 3 months
  • On a tricyclic antidepressant, monoamine oxidase inhibitor, esketamine, or vortioxetine.
  • A history of clinically diagnosed dementia of any type
  • Previous systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening
  • Has a or body weight that will interfere with participation in the trial
  • Type I or Type II diabetes requiring insulin
  • Clinically significant abnormalities
  • Participation in another clinical trial of a drug or device
  • Trial participants who in the opinion of the Investigator exhibit physical, cognitive, or language impairments of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • Positive testing for , surface antigen, or antibodies at Screening.
  • Participants with a history of drug abuse or addiction in the past 2 years
  • Current use of cannabis/marijuana, or tetrahydrocannabinol-containing medications.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    10 mg Xanamem™

    10 mg Xanamem™ capsule, to be administered orally once every morning with or without food

    Drug: Xanamem™

  • Placebo comparator
    Placebo

    Placebo capsule, to be administered orally once every morning with or without food

    Drug: Placebo

Interventions

  • DrugUE2343Studies of UE2343UE2343 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.

    Also known as: UE2343

  • DrugPlacebo

    Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.

06

What researchers measure

Primary outcomes

  1. Efficacy of Xanamem on attention, including working memory

    Change from Baseline to EOT in an Attention Composite of a Cognitive Test Battery (CTB) (Detection, Identification, and One Back tests)

    Time frame: 6 Weeks (Baseline to Week 6 (end of treatment (EOT)))

  2. Evaluation of the short-term safety and tolerability of Xanamem

    Incidence and severity of treatment-emergent adverse events (TEAEs) Incidence of serious adverse events (SAEs) and SUSARs

    Time frame: 6 Weeks (Baseline to Week 6 (EOT))

Secondary outcomes

  1. Determine the effects of Xanamem on depressive symptoms

    Change from Baseline to EOT on the Montgomery-Åsberg Depression Rating Scale (MADRS). The MADRS is a 10-item diagnostic questionnaire used to assess the severity of depressive episodes and is designed to be sensitive to treatment effects. Each item is scored from 0 to 6, and overall scores range from 0 to 60. Higher scores indicate greater severity.

    Time frame: 6 Weeks (Baseline to Week 6 (EOT))

07

Study locations

12 sites
  • Paratus Clinical Research Western Sydney
    Blacktown, New South Wales, Australia
  • Genesis Research Services
    Newcastle, New South Wales, Australia
  • Paratus Clinical Research Brisbane
    Brisbane, Queensland, Australia
  • USC Clinical Trials
    Sippy Downs, Queensland, Australia
  • Ramsay Clinic Albert Road
    Melbourne, Victoria 3004, Australia
  • Monash Alfred Psychiatry Research Centre
    Melbourne, Victoria, Australia
  • NeuroCentrix
    Noble Park, Victoria, Australia
  • St Pancras Clinical Research
    London, EC2Y 8EA, United Kingdom
  • Clerkenwell Health
    London, W1G 8DR, United Kingdom
  • MAC Clinical Research - Manchester
    Manchester, M13 9NQ, United Kingdom
  • Glasgow Memory Clinic
    Motherwell, ML1 4UF, United Kingdom
  • MAC Clinical Research - South Yorkshire
    Tankersley, S75 3DL, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jul 2024, 19 months.

Of 99 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 19 months is above that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2022
First posted
Dec 20, 2022
StartActual
Nov 28, 2022
Primary completionActual
Jul 1, 2024
CompletionActual
Jul 1, 2024
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05657691
Lead sponsor
Actinogen Medical
Collaborators
AXIOM Real Time Metrics
Responsible party
Sponsor
First posted
Dec 20, 2022
Start date
Nov 28, 2022
Primary completion
Jul 1, 2024
Completion
Jul 1, 2024
Last update
Jan 22, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UE2343

Start the discussion